Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial
A multicentre randomized trial involving 787 patients (full analysis set) discharged from four tertiary hospitals with chronic HF who were randomized to SM (n=391) or INT-HF-MP (n = 396). Mean age was 74±12 years, 65% had HF with a reduced ejection fraction (31.4 ± 8.9%) and 14% were remote-dwelling...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Oxford University Press
2017
|
| Online Access: | http://hdl.handle.net/20.500.11937/56835 |
| _version_ | 1848759948766347264 |
|---|---|
| author | Scuffham, P. Ball, J. Horowitz, J. Wong, C. Newton, P. Macdonald, P. McVeigh, J. Rischbieth, A. Emanuele, N. Carrington, M. Reid, Christopher Chan, Y. Stewart, S. |
| author_facet | Scuffham, P. Ball, J. Horowitz, J. Wong, C. Newton, P. Macdonald, P. McVeigh, J. Rischbieth, A. Emanuele, N. Carrington, M. Reid, Christopher Chan, Y. Stewart, S. |
| author_sort | Scuffham, P. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | A multicentre randomized trial involving 787 patients (full analysis set) discharged from four tertiary hospitals with chronic HF who were randomized to SM (n=391) or INT-HF-MP (n = 396). Mean age was 74±12 years, 65% had HF with a reduced ejection fraction (31.4 ± 8.9%) and 14% were remote-dwelling. Study groups were well matched. According to Green, Amber, Red Delineation of rIsk And Need in HF (GARDIAN-HF) profiling, regardless of location, patients in the INT-HF-MP received a combination of face-to-face (home visits) and structured telephone sup- port (STS); only 9% (‘low risk’) were designated to receive the same level of management as the SM group. The median cost in 2017 Australian dollars (A$1 equivalent to EUR e 0.7) of applying INT-HF-MP was significantly greater than SM ($152 vs. $121 per patient per month; P<0.001), However, at 12 months, there was no difference in total health care costs for the INT-HF-MP vs. SM group (median $1579, IQR $644 to $3717 vs. $1450, IQR $564 to $3615 per patient per month, respectively). This reflected minimal differences in all-cause mortality (17.7% vs. 18.4%; P=0.848) and recurrent hospital stay (18.6 ± 26.5 vs. 16.6 ± 24.8 days; P=0.199) between the INT-HF-MP and SM groups, respectively. |
| first_indexed | 2025-11-14T10:08:00Z |
| format | Journal Article |
| id | curtin-20.500.11937-56835 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:08:00Z |
| publishDate | 2017 |
| publisher | Oxford University Press |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-568352018-01-05T06:07:16Z Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial Scuffham, P. Ball, J. Horowitz, J. Wong, C. Newton, P. Macdonald, P. McVeigh, J. Rischbieth, A. Emanuele, N. Carrington, M. Reid, Christopher Chan, Y. Stewart, S. A multicentre randomized trial involving 787 patients (full analysis set) discharged from four tertiary hospitals with chronic HF who were randomized to SM (n=391) or INT-HF-MP (n = 396). Mean age was 74±12 years, 65% had HF with a reduced ejection fraction (31.4 ± 8.9%) and 14% were remote-dwelling. Study groups were well matched. According to Green, Amber, Red Delineation of rIsk And Need in HF (GARDIAN-HF) profiling, regardless of location, patients in the INT-HF-MP received a combination of face-to-face (home visits) and structured telephone sup- port (STS); only 9% (‘low risk’) were designated to receive the same level of management as the SM group. The median cost in 2017 Australian dollars (A$1 equivalent to EUR e 0.7) of applying INT-HF-MP was significantly greater than SM ($152 vs. $121 per patient per month; P<0.001), However, at 12 months, there was no difference in total health care costs for the INT-HF-MP vs. SM group (median $1579, IQR $644 to $3717 vs. $1450, IQR $564 to $3615 per patient per month, respectively). This reflected minimal differences in all-cause mortality (17.7% vs. 18.4%; P=0.848) and recurrent hospital stay (18.6 ± 26.5 vs. 16.6 ± 24.8 days; P=0.199) between the INT-HF-MP and SM groups, respectively. 2017 Journal Article http://hdl.handle.net/20.500.11937/56835 10.1093/eurheartj/ehx259 http://creativecommons.org/licenses/by-nc/4.0/ Oxford University Press fulltext |
| spellingShingle | Scuffham, P. Ball, J. Horowitz, J. Wong, C. Newton, P. Macdonald, P. McVeigh, J. Rischbieth, A. Emanuele, N. Carrington, M. Reid, Christopher Chan, Y. Stewart, S. Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial |
| title | Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial |
| title_full | Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial |
| title_fullStr | Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial |
| title_full_unstemmed | Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial |
| title_short | Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial |
| title_sort | standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial |
| url | http://hdl.handle.net/20.500.11937/56835 |